These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23100242)

  • 41. Peroxisome proliferator-activated receptor δ agonist GW1516 attenuates diet-induced aortic inflammation, insulin resistance, and atherosclerosis in low-density lipoprotein receptor knockout mice.
    Bojic LA; Burke AC; Chhoker SS; Telford DE; Sutherland BG; Edwards JY; Sawyez CG; Tirona RG; Yin H; Pickering JG; Huff MW
    Arterioscler Thromb Vasc Biol; 2014 Jan; 34(1):52-60. PubMed ID: 24158519
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hydrogen isotope ratio mass spectrometry and high-resolution/high-accuracy mass spectrometry in metabolite identification studies: detecting target compounds for sports drug testing.
    Thevis M; Piper T; Horning S; Juchelka D; Schänzer W
    Rapid Commun Mass Spectrom; 2013 Sep; 27(17):1904-12. PubMed ID: 23939956
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preventive doping control screening analysis of prohibited substances in human urine using rapid-resolution liquid chromatography/high-resolution time-of-flight mass spectrometry.
    Vonaparti A; Lyris E; Angelis YS; Panderi I; Koupparis M; Tsantili-Kakoulidou A; Peters RJ; Nielen MW; Georgakopoulos C
    Rapid Commun Mass Spectrom; 2010 Jun; 24(11):1595-609. PubMed ID: 20486255
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and characterization of urinary prenylamine metabolites by means of liquid chromatography-tandem mass spectrometry.
    Beuck S; Sigmund G; Koch A; Schänzer W; Pokrywka A; Kwiatkowska D; Thevis M
    Drug Test Anal; 2012 Sep; 4(9):701-16. PubMed ID: 22786790
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urine analysis concerning xenon for doping control purposes.
    Thevis M; Piper T; Geyer H; Schaefer MS; Schneemann J; Kienbaum P; Schänzer W
    Rapid Commun Mass Spectrom; 2015 Jan; 29(1):61-6. PubMed ID: 25462364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Investigation of the in vitro metabolism of the emerging drug candidate S107 for doping-preventive purposes.
    Beuck S; Schänzer W; Thevis M
    J Mass Spectrom; 2011 Feb; 46(2):112-30. PubMed ID: 21254313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influences of musk administration on the doping test.
    He Y; Wang J; Liu X; Xu Y; He Z
    Steroids; 2013 Nov; 78(11):1047-52. PubMed ID: 23891647
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing.
    Beuck S; Möller I; Thomas A; Klose A; Schlörer N; Schänzer W; Thevis M
    Anal Bioanal Chem; 2011 Aug; 401(2):493-505. PubMed ID: 21455647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.
    Knoop A; Thomas A; Thevis M
    Rapid Commun Mass Spectrom; 2019 Feb; 33(4):371-380. PubMed ID: 30394592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Screening of in vitro synthesised metabolites of 4,9,11-trien-3-one steroids by liquid chromatography mass spectrometry.
    Kuuranne T; Pystynen KH; Thevis M; Leinonen A; Schänzer W; Kostiainen R
    Eur J Mass Spectrom (Chichester); 2008; 14(3):181-9. PubMed ID: 18708698
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hyphenated mass spectrometric techniques-indispensable tools in clinical and forensic toxicology and in doping control.
    Maurer HH
    J Mass Spectrom; 2006 Nov; 41(11):1399-413. PubMed ID: 17051522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determination of therapeutics with growth-hormone secretagogue activity in human urine for doping control purposes.
    Thevis M; Wilkens F; Geyer H; Schänzer W
    Rapid Commun Mass Spectrom; 2006; 20(22):3393-402. PubMed ID: 17051614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The use of in vitro technologies coupled with high resolution accurate mass LC-MS for studying drug metabolism in equine drug surveillance.
    Scarth JP; Spencer HA; Timbers SE; Hudson SC; Hillyer LL
    Drug Test Anal; 2010 Jan; 2(1):1-10. PubMed ID: 20878880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro metabolism of the REV-ERB agonist SR-9009 and subsequent detection of metabolites in associated routine equine plasma and urine doping control samples.
    Cutler C; White DL; Viljanto M
    Drug Test Anal; 2022 Jan; 14(1):169-174. PubMed ID: 34224639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Detection of prohibited substances by liquid chromatography tandem mass spectrometry for sports doping control.
    Ahrens BD; Starcevic B; Butch AW
    Methods Mol Biol; 2012; 902():115-28. PubMed ID: 22767112
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mass spectrometry in sports drug testing: Structure characterization and analytical assays.
    Thevis M; Schänzer W
    Mass Spectrom Rev; 2007; 26(1):79-107. PubMed ID: 16888758
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Veterinary medicines and competition animals: the question of medication versus doping control.
    Toutain PL
    Handb Exp Pharmacol; 2010; (199):315-39. PubMed ID: 20204593
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mass spectrometric identification and characterization of new clomiphene metabolites in human urine by liquid chromatography-quadrupole time-of-flight tandem mass spectrometry.
    Lu J; He G; Wang X; Xu Y; Wu Y; Dong Y; He Z; Liu X; Bo T; Ouyang G
    J Chromatogr A; 2012 Jun; 1243():23-32. PubMed ID: 22579489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative in vitro metabolism of the 'designer' steroid estra-4,9-diene-3,17-dione between the equine, canine and human: identification of target metabolites for use in sports doping control.
    Scarth JP; Clarke AD; Teale P; Pearce CM
    Steroids; 2010 Oct; 75(10):643-52. PubMed ID: 20381511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolism of androsta-1,4,6-triene-3,17-dione and detection by gas chromatography/mass spectrometry in doping control.
    Parr MK; Fusshöller G; Schlörer N; Opfermann G; Piper T; Rodchenkov G; Schänzer W
    Rapid Commun Mass Spectrom; 2009 Jan; 23(2):207-18. PubMed ID: 19089863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.